12月24日，百奥赛图（688796.SH/02315.HK）发行并于香港联合交易所有限公司上市的股份（以下简称"H股"）正式调入港股通标的名单。 自此，中国内地符合条件的机构及个人投资者，可通过上海证券交易所、深圳证券交易所，直接投资百奥赛图H股。 市场反应迅速，公告当日，公司H股收盘大涨22.23%，A股亦联动上涨3.42%。"入通"成为公司继构建"A+H"双上市平台后，在资本市场的又 一里程碑，也标志着公司在资本可达性、市场认可度与长期投资价值等方面迈入全新阶段。 数据来源：上交所，格隆汇整理 "入通"影响几何？ 百奥赛图H股成功纳入港股通标的，其直接影响首先反映在价格表现上："入通"首日，其H股股价大幅收涨22.23%。这一市场表现并非孤例， 将其置于更广阔的样本中观察，能更清晰地看到"入通"的普遍意义。 参考今年以来A+H上市公司的轨迹，根据WIND数据（截至2025年12月24日），在年内已完成两地上市的20家公司中，已有18家成功"入 通"。自纳入港股通至今，这18家公司的股价平均累计涨幅达到12.30%，其中约66.67%的公司实现了正收益。这表明，"入通"本身已成为一个 积极的资本市场催化剂 ...

Core Viewpoint - CITIC Securities indicates that the A-share year-end rally has begun, driven by positive signals from the recent eight consecutive days of gains in the Shanghai Composite Index, following the completion of a mid-term adjustment [1] Market Outlook - The optimistic expectations from institutional investors suggest that the spring market rally may start earlier than usual [1] - Improvements in overseas liquidity and risk, alongside the conclusion of adjustments in AI models in the U.S., contribute to a favorable market environment [1] - The release of numerous policies and events related to the 14th Five-Year Plan has heightened investor expectations [1] Sector Focus - Key sectors to watch include non-ferrous metals and AI computing power, with commercial aerospace remaining the primary market focus [1] - Secondary themes include the Hainan Free Trade Zone, controllable nuclear fusion, and humanoid robots [1] Specific Sector Insights - The upgrade of NVIDIA's Rubin architecture is expected to boost the entire AI computing power industry chain, benefiting sectors such as optical fibers, liquid-cooled servers, CPOs, and storage chips [1] - Non-ferrous metals continue to maintain a rising trend due to price increases in lithium carbonate, gold, silver, copper, and aluminum, indicating a high level of industry prosperity [1] - The market's thematic focus remains on commercial aerospace, with secondary attention on the Hainan Free Trade Zone, controllable nuclear fusion, and humanoid robots [1] Investment Highlights - Key sectors for investment consideration include non-ferrous metals, commercial aerospace, AI, humanoid robots, controllable nuclear fusion, innovative pharmaceuticals, non-bank financials, and the Hainan Free Trade Zone [1]

Group 1 - The core viewpoint of the articles indicates that various industry sectors are showing mixed performance, with metals, military, power equipment, and electronics sectors leading in gains, while consumer and stable sectors like beauty care, social services, banking, and coal are experiencing slight declines [1] - The non-ferrous metals sector is performing strongly, and the military sector is also showing overall strength, driven by the robust performance of the energy storage and battery supply chain, which positively impacts the power equipment sector [1] - Specific sub-industries such as semiconductors, PCBs, and optical modules are experiencing upward trends, while certain consumer sectors are seeing minor declines [1] Group 2 - The recommendation is to maintain a certain level of positions for long positions until upward pressure is confirmed, with a focus on growth sectors that have strong certainty, such as AI computing hardware, domestic semiconductor equipment, and innovative drugs [2] - Attention should be given to cyclical sectors like industrial and energy metals, which are expected to have improved supply-demand dynamics next year, while caution is advised in the precious metals sector due to potential price corrections [2] - Non-bank financial sectors with strong beta attributes may be worth monitoring, while the consumer sector should focus on discretionary consumption sub-sectors [2]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The number of innovative drugs listed in China continues to grow, with domestic products accounting for approximately half of the total market share. The R&D capabilities for innovative drugs in China are also increasing, attracting global attention. Notably, the number and value of domestic innovative drug business development (BD) transactions have reached new highs, with ADC, bispecific antibodies, small nucleic acids, and CAR-T being the four key R&D directions to watch in 2026 [15][21][22] - The Chinese innovative drug market has seen a significant increase in the number of new drug applications (NDA), with domestic products making up a growing proportion. From 2017 to 2024, the number of innovative drugs listed in China rose from 41 to 92, with domestic products accounting for 50% of the total by 2024 [17][21] - The report highlights that the license-out transaction volume and total amount for Chinese companies reached $92.03 billion in the first three quarters of 2025, a 77% increase compared to the total for 2024. The upfront payment for license-out transactions has also surpassed the total financing amount in the primary market for the same period [22][25] Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a year-to-date increase of 14.29%, while the Hang Seng Healthcare Index has surged by 62.29% [3][8] - The report notes that the pharmaceutical sector has experienced fluctuations, with raw materials and medical devices showing positive growth [8] R&D Progress and Company Dynamics - The report provides an overview of the R&D progress for innovative and modified drugs, including approvals and clinical applications [5] - It lists key companies to watch in various sub-sectors, including innovative drugs, research services, and medical devices, with specific recommendations for companies like Innovent Biologics, Hengrui Medicine, and WuXi AppTec [11][12] Market Insights and Regulatory Observations - The report tracks the price-to-earnings ratio of the pharmaceutical index, noting that it is currently lower than historical averages [5] - It emphasizes the importance of the regulatory environment and market dynamics in shaping the future of the pharmaceutical industry [5]

医药生物 2025 年 12 月 28 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2024-12 2025-04 2025-08 医药生物 沪深300 相关研究报告 《推荐 CXO+科研服务板块的估值切 换机会—行业周报》-2025.12.21 《2025 国谈结果公布，关注相关公司 投资机会—行业周报》-2025.12.14 《必贝特在小核酸领域的差异化布局 —行业周报》-2025.12.7 瑞博生物通过港交所 IPO 聆讯，上市在即 ——行业周报 | 余汝意（分析师） | 巢舒然（分析师） | | --- | --- | | yuruyi@kysec.cn | chaoshuran@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790525110001 | chaoshuran@kysec.cn 证书编号：S0790525110001 瑞博生物港交所 IPO 申请通过聆讯，上市在即 2025 年 12 月 21 日，瑞博生物港交所 IPO 申请通过聆讯，即将挂牌上市。瑞博 生物成立于 2007 年，是一家 ...

Market Review - A-shares led global indices with major broad-based indices generally rising, particularly the CSI 500 and ChiNext, while the Shanghai Composite Index recorded an eight-day winning streak approaching 4000 points [1] - The market liquidity is abundant, with A-share trading volume continuing to expand, reaching over 2 trillion yuan on Friday, and the financing balance exceeding 2.5 trillion yuan, setting a historical high [1] - In terms of style, small-cap and growth styles outperformed, with sectors such as non-ferrous metals, defense, and electric equipment leading gains, while beauty care, social services, and banking sectors declined [1] Market Outlook - Multiple funds are rushing to capitalize on the "spring rally," with a focus on buying on dips. The uncertainty in overseas monetary policy is dissipating, and the upcoming Chinese New Year and "Two Sessions" are expected to support risk appetite [2] - The "spring rally" conditions are accumulating, with key factors including reasonable valuation levels, a loose liquidity environment, and catalysts to boost risk appetite such as domestic policies and external risk mitigation [2] - The latest risk premium for the CSI 300 is at the median level of the past decade, indicating reasonable A-share valuations, while the central bank emphasizes continued implementation of a moderately loose monetary policy [2] Fund Flows - The net subscription of A500 ETFs has become one of the important sources of incremental funds for A-shares at year-end, with a cumulative net subscription of 90.8 billion yuan in December, the highest since April [3] - The top six A500 ETF products saw a net inflow of 97.2 billion yuan since December, reflecting accelerated inflow of institutional funds [3] Financing and Currency Trends - The financing balance of A-shares reached a historical high of 2.53 trillion yuan as of December 25, with a net buy of 72 billion yuan in financing funds since December, indicating a recovery in market sentiment [4] - The strong performance of the RMB is favorable for foreign capital inflow, with the offshore RMB briefly surpassing the 7.0 mark against the USD, reflecting market confidence in the Chinese economy [4] Industry Allocation Recommendations - Focus on growth themes benefiting from industrial policy support, such as domestic substitution, robotics, commercial aerospace, nuclear fusion, innovative drugs, and energy storage [5] - Pay attention to sectors benefiting from "anti-involution" price increases, such as chemicals, energy metals, and new energy [5] - Look for potential catalytic opportunities in the consumer sector due to the deepening of consumption policies [5]

Group 1 - The core point of the article highlights the upcoming annual report disclosures for listed companies, with a focus on those expected to show significant performance growth in 2025 [2] - As of December 26, 2023, 34 listed companies in A-shares have forecasted their 2025 annual performance, with 23 companies expecting positive results, representing 67.65% of the total [2] - Key industries showing notable performance growth include semiconductors, consumer electronics, biomedicine, machinery, and new energy [2] Group 2 - Among the companies forecasting net profit growth, 17 companies expect an increase of over 10%, while 11 anticipate over 20%, and 5 expect over 50% [3] - The top three companies in terms of expected net profit growth are Bai Ao Sai Tu, Xi Hua Technology, and Sanhua Intelligent Control, with projected increases of 303.57%, 52.61%, and 50.00% respectively [3] - 14 companies are expected to report net profits exceeding 100 million yuan, with 6 companies surpassing 500 million yuan, and 4 companies exceeding 1.5 billion yuan [3] Group 3 - Leading companies are showing strong performance recovery, with Luxshare Precision expected to achieve a net profit of 165.18 billion to 171.86 billion yuan, reflecting a growth of 23.59% to 28.59% year-on-year [4] - Luxshare attributes its growth to a deepened global strategy and enhanced cost-effective manufacturing solutions, alongside investments in AI, data centers, and emerging fields [4] Group 4 - As the annual report disclosure season approaches, companies with better-than-expected performance are likely to attract market attention, with a focus on sectors like artificial intelligence, semiconductors, robotics, innovative pharmaceuticals, and new energy [5] - Companies that announce significant profit increases early are expected to draw more market funds, particularly industry leaders with high growth forecasts [5]

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

每经记者｜林姿辰 陈星 每经编辑｜文多 2025年，生物医药正迎来历史性跨越,无论是国内获 批上市的创新药数量再创新高，还是中国创新药对外授权 总金额突破1000亿美元，其背后离不开政策制定者的顶层 设计、产业从业者的深耕细作,以及普通大众的坚定信 心。这份比金子更珍贵的精神财富，共同铸就了改写国人 健康答案的关键瞬间。 每经记者 | 林姿辰 陈星 阿尔茨海默病新药开出中国 首方 /U/ZD ٺ德 一生制药与辉瑞授权交易额高 达60.5亿美元 中国侵入式脑机接口进入临床 试验阶段 政府工作报告再提"创新药" 拥亏 创新药龙头百济神州首次实现 扣亏为盈 创新药临床申请审批开"2倍速" 7 % 嶺顶 百利天恒临床数据惊艳全球 HPV疫苗进入国家免疫规划 首版商保创新药目录发布 爆发 中国创新药BD总额破千亿美元 普京 新闻：2025年3月，创新药在基本医疗卫生服务中被划重点："健全药品价格形成机制，制定创新药目录，支持创新药发展。"在年初就为2025年创新药行 业发展渲染了明快色调。 y 9 % 暖心 2025年的中国医药行业步履铿锵、亮点纷呈，而作为行业发展的核心引擎，生物医药正迎来属于自己的历史性跨越。截至1 ...

Investment Rating - The report maintains a "Buy" rating for the overseas education sector, particularly highlighting New Oriental as a key player [10]. Core Insights - The overseas education sector is experiencing improved operational efficiency and accelerated profit margin expansion, with New Oriental expected to report a revenue of $1.165 billion for Q2 FY26, representing a year-on-year growth of 12.2% [5][10]. - The report anticipates a significant increase in non-GAAP net profit for New Oriental, projected at $63 million, which is a 77.8% increase year-on-year, with a non-GAAP net profit margin of 5.4%, expanding by 2 percentage points [5][10]. Summary by Sections 1. Overseas Education - **Market Review**: The education index rose by 2.8% in the week of December 19-25, outperforming the Hang Seng Index by 1.8 percentage points, with a year-to-date increase of 13.1% [4]. - **Company Update**: New Oriental's revenue is expected to reach $1.165 billion, with the education business (including cultural tourism) contributing $957 million, a growth of 11% year-on-year [5][10]. - **Study Abroad Business**: The revenue from study abroad exam training and consulting is projected to decline by 3% to $242 million, reflecting a slowdown in growth due to high base effects from the previous year [2][5]. - **New Business Growth**: New business segments, including K9 competency training and learning machine services, are expected to grow by 21% to $364 million, driven by differentiated offerings for primary and secondary education [3][6]. - **Operating Profit Margin Improvement**: Despite a slowdown in high-margin study abroad business, the increase in competency business margins is expected to offset this. The non-GAAP operating profit margin is projected to expand by approximately 2 percentage points to 4.7% [6][10]. 2. Overseas Pharmaceuticals - **Market Review**: The Hang Seng Healthcare Index saw a slight increase of 0.02%, underperforming the Hang Seng Index by 1.24 percentage points [12]. - **Key Events**: Notable transactions include Sanofi's $2.2 billion acquisition of vaccine company Dynavax, which has a marketed hepatitis B vaccine and a promising shingles vaccine candidate [14]. - **Investment Recommendations**: The report suggests focusing on innovative drug companies with active business development opportunities and clinical progress in key pipelines, including companies like BeiGene and Innovent Biologics [15]. 3. Overseas Social Services - **Ctrip's Q3 Performance**: Ctrip reported a 16% year-on-year revenue increase to $18.4 billion, with strong performance across various business segments, particularly in international OTA platforms [17]. - **Tongcheng Travel's Q3 Performance**: Tongcheng Travel's revenue grew by 10% to $5.5 billion, with a notable increase in accommodation and core OTA business revenues [18]. - **Key Focus**: The report highlights potential growth in the outbound travel sector and the importance of hotel management services as additional growth drivers [19].